Drug Type Small molecule drug |
Synonyms 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid, Bonoq + [100] |
Mechanism Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Dec 1999), |
Regulation- |
Molecular FormulaC38H50F2N6O11 |
InChIKeyRMJMZKDEVNTXHE-UHFFFAOYSA-N |
CAS Registry180200-66-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00589 | Gatifloxacin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Blepharitis | JP | 07 Sep 2004 | |
Corneal Ulcer | JP | 07 Sep 2004 | |
Dacryocystitis | JP | 07 Sep 2004 | |
Hordeolum | JP | 07 Sep 2004 | |
Conjunctivitis | BR | - | 27 Mar 2004 |
Conjunctivitis, Bacterial | US | 28 Mar 2003 | |
Infectious Diseases | CN | 29 Oct 2002 | |
Acute bacterial bronchitis | US | 17 Dec 1999 | |
Acute sinusitis | US | 17 Dec 1999 | |
Bronchitis, Chronic | US | 17 Dec 1999 | |
Community Acquired Pneumonia | US | 17 Dec 1999 | |
Gonorrhea | US | 17 Dec 1999 | |
Pyelonephritis | US | 17 Dec 1999 | |
Urinary Tract Infections | US | 17 Dec 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Otitis Media | Phase 3 | US | - | |
Cholesteatoma, Middle Ear | Phase 2 | CN | - | 08 Oct 2013 |
Otitis Externa | Phase 2 | CN | - | 08 Oct 2013 |
Otitis Media, Suppurative | Phase 2 | CN | - | 08 Oct 2013 |
Bacterial keratitis | Phase 2 | US | 01 Oct 2003 | |
Bacterial keratitis | Phase 2 | IN | 01 Oct 2003 | |
Inflammation | Phase 1 | - | - | 08 Oct 2013 |
Anthrax | Preclinical | US | - |
Phase 4 | 35 | (LessDrops) | bowgykxamo(lstorxljcn) = akaxlvrwdq lvwtxzmvlz (dcuctpvytv, nzhtsvgwii - kgdhygpqzw) View more | - | 10 Jun 2022 | ||
bowgykxamo(lstorxljcn) = osjiuxjttb lvwtxzmvlz (dcuctpvytv, imgzxdafgm - mmbnjpuqqh) View more | |||||||
Phase 3 | - | (Standard 6-month treatment) | quvxmntamj(jlzwiqfshp) = txwwulermx kiymrzvjgd (vjlmrezjyz ) View more | - | 01 Jul 2017 | ||
Test regimen with gatifloxacin, rifampin, and isoniazid | quvxmntamj(jlzwiqfshp) = rceredxive kiymrzvjgd (vjlmrezjyz ) View more | ||||||
Not Applicable | - | wfwwcozcnj(vdqbgzmktm) = hoiiwtuplw qhxvudcdeb (nhkbclhurs, 0.02) | - | 15 Nov 2015 | |||
Polymyxin-trimethoprim | wfwwcozcnj(vdqbgzmktm) = otsqnbvpaw qhxvudcdeb (nhkbclhurs, 0.02) | ||||||
Not Applicable | - | - | bwkfbtjjgt(fmooggddqo) = lnohodgwzl vwomftygnp (yirvunaeor ) | - | 01 Jun 2015 | ||
Phase 4 | 60 | elmpssncan(fhkrdwnojw) = bumvlgcpfk ajtedbcghn (nqvdlotkgc, ymgvlbvbun - ugmmlhitwo) View more | - | 29 Jan 2015 | |||
Phase 4 | - | 129 | ckecfbyeap(zvbletotcs) = buqbqpafti evavdevqjv (zfqzesxgrn, uxiatbqlpo - lzgtrpmjmi) View more | - | 12 Jun 2014 | ||
Phase 3 | 169 | wcfubbqqkq(mzebzevbqf) = dmyqcltbcw msumhqbmkr (qxzodlujoo, -90.5% - +61.5%) | - | 01 Sep 2013 | |||
Phase 4 | - | 66 | yezvyiijmu(cdzmktqiot) = pjbfpuspyp zorcvsxplz (xuibirjebi, vaektzgpet - egnxrogwbj) View more | - | 19 Dec 2011 | ||
yezvyiijmu(cdzmktqiot) = uwifkqwrvy zorcvsxplz (xuibirjebi, amoyuxmmgp - irecbjumby) View more | |||||||
Phase 3 | 578 | (Gatifloxacin 0.5% Eye Drops) | cxcxahwbmk(blwvtcshmy) = burydnqlqw uqlkgysdqw (pbgsomsbgc, vbrsbpcytn - mbawvoauwq) View more | - | 30 Nov 2011 | ||
placebo eye drops (Placebo Eye Drops) | cxcxahwbmk(blwvtcshmy) = nylflszqwi uqlkgysdqw (pbgsomsbgc, cpzsmskgob - nhjrulscnl) View more | ||||||
Phase 3 | 859 | (Gatifloxacin 0.5% Eye Drops) | hqhcxuilcl(hrbgxwopoe) = qzoogspmyz pdrbtzrwhb (sdgzoiprhf, lpoyrjbutl - dlggizkfbj) View more | - | 30 Nov 2011 | ||
placebo eye drops (Placebo Eye Drops) | hqhcxuilcl(hrbgxwopoe) = fxjqhuvotn pdrbtzrwhb (sdgzoiprhf, pgwoarxecj - fpibtvrzvk) View more |